154 related articles for article (PubMed ID: 38281290)
21. Two cases of rapid progression of esophageal varices after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
Furusawa A; Naganuma A; Suzuki Y; Hoshino T; Yasuoka H; Tamura Y; Naruse H; Hatanaka T; Kakizaki S
Clin J Gastroenterol; 2022 Apr; 15(2):451-459. PubMed ID: 35179703
[TBL] [Abstract][Full Text] [Related]
22. Partial Splenic Embolization for Lenvatinib Therapy-associated Thrombocytopenia Among Patients With Hepatocellular Carcinoma.
Sato N; Beppu T; Kinoshita K; Yuki H; Suyama K; Yuruki H; Motohara T; Chiyonaga S; Akahoshi S
Anticancer Res; 2019 Dec; 39(12):6895-6901. PubMed ID: 31810959
[TBL] [Abstract][Full Text] [Related]
23. Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma.
Hirooka M; Ochi H; Hiraoka A; Koizumi Y; Matsuura B; Joko K; Michitaka K; Abe M; Hiasa Y
Intern Med; 2019 Mar; 58(6):791-795. PubMed ID: 30333428
[TBL] [Abstract][Full Text] [Related]
24. [A Case of Combined Hepatocellular Carcinoma and Cholangiocarcinoma with Multidisciplinary Treatment Including Lenvatinib].
Furuya K; Ioka T; Shindo Y; Tokumitsu Y; Matsui H; Matsukuma S; Nakajima M; Yamada K; Watanabe Y; Tomochika S; Yoshida S; Iida M; Suzuki N; Takeda S; Nagano H
Gan To Kagaku Ryoho; 2021 Dec; 48(13):1694-1696. PubMed ID: 35046300
[TBL] [Abstract][Full Text] [Related]
25. Rechallenge With Lenvatinib After Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma.
Komatsu S; Yano Y; Kido M; Kuramitsu K; Gon H; Fukushima K; Urade T; So S; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
Anticancer Res; 2022 Nov; 42(11):5479-5486. PubMed ID: 36288850
[TBL] [Abstract][Full Text] [Related]
26. Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma.
Kunimoto H; Shakado S; Tanaka T; Takata K; Yamauchi R; Fukuda H; Tsuchiya N; Yokoyama K; Morihara D; Takeyama Y; Hirai F; Sakisaka S
Oncology; 2020; 98(11):779-786. PubMed ID: 32877911
[TBL] [Abstract][Full Text] [Related]
27. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma.
Catalano M; Casadei-Gardini A; Vannini G; Campani C; Marra F; Mini E; Roviello G
Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1353-1365. PubMed ID: 34289756
[TBL] [Abstract][Full Text] [Related]
28. Adaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosis.
Mukozu T; Nagai H; Matsui D; Mohri K; Watanabe G; Yoshimine N; Amanuma M; Kobayashi K; Ogino Y; Matsukiyo Y; Matsui T; Daido Y; Wakui N; Shinohara M; Momiyama K; Higai K; Igarashi Y
Cancer Chemother Pharmacol; 2022 Jan; 89(1):11-20. PubMed ID: 34628536
[TBL] [Abstract][Full Text] [Related]
29. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease.
Perera S; Kelly D; O'Kane GM
Curr Oncol; 2020 Nov; 27(Suppl 3):S165-S172. PubMed ID: 33343210
[TBL] [Abstract][Full Text] [Related]
30. Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma.
Kotani K; Enomoto M; Okada M; Yoshida K; Motoyama H; Fujii H; Hagihara A; Uchida-Kobayashi S; Morikawa H; Murakami Y; Tamori A; Kawada N
Clin J Gastroenterol; 2019 Aug; 12(4):355-360. PubMed ID: 31020569
[TBL] [Abstract][Full Text] [Related]
31. A case of conversion hepatectomy for huge ruptured hepatocellular carcinoma after transarterial embolization and lenvatinib therapy.
Naganuma A; Suzuki Y; Hoshino T; Yasuoka H; Tamura Y; Naruse H; Tanaka H; Hirai K; Sakamoto I; Ogawa T; Hatanaka T; Kakizaki S
Clin J Gastroenterol; 2022 Feb; 15(1):177-184. PubMed ID: 34811701
[TBL] [Abstract][Full Text] [Related]
32. Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients.
Persano M; Rimini M; Tada T; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Yoo C; Lonardi S; Tovoli F; Kumada T; Sakamoto N; Iwamoto H; Aoki T; Chon HJ; Himmelsbach V; Niizeki T; Montes M; Vivaldi C; Soldà C; Stefanini B; Hiraoka A; Sho T; Nishida N; Steup C; Iavarone M; Di Costanzo G; Marra F; Tamburini E; Cabibbo G; Foschi FG; Silletta M; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Campani C; Amadeo E; Rossari F; Burgio V; Cascinu S; Scartozzi M; Casadei-Gardini A
Eur J Cancer; 2023 Aug; 189():112933. PubMed ID: 37385069
[TBL] [Abstract][Full Text] [Related]
33. [Surgical Resection and Adjuvant Chemotherapy for Early Multiple Peritoneal Recurrence after Rejection of Hepatocellular Carcinoma-A Case Report].
Yamaguchi S; Onoe T; Fujii T; Shibata Y; Tazuma S; Akimoto S; Sada H; Shimada N; Tazawa H; Suzuki T; Sudo T; Shimizu Y; Tashiro H
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1450-1452. PubMed ID: 38303304
[TBL] [Abstract][Full Text] [Related]
34. Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report.
Liu Z; Li X; He X; Xu Y; Wang X
BMC Cancer; 2019 Nov; 19(1):1062. PubMed ID: 31703571
[TBL] [Abstract][Full Text] [Related]
35. A patient alive without disease 32 months after conversion surgery following lenvatinib treatment for hepatocellular carcinoma with a tumor thrombus originating in the middle hepatic vein and reaching the right atrium via the suprahepatic vena cava: a case report.
Gyoda Y; Ichida H; Kawano F; Takeda Y; Yoshioka R; Imamura H; Mise Y; Fukumura Y; Saiura A
Clin J Gastroenterol; 2024 Apr; 17(2):311-318. PubMed ID: 38277091
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Liu J; Yang L; Wei S; Li J; Yi P
J Cancer Res Clin Oncol; 2023 Nov; 149(17):16191-16201. PubMed ID: 37658861
[TBL] [Abstract][Full Text] [Related]
37. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
Han Y; Zhi WH; Xu F; Zhang CB; Huang XQ; Luo JF
World J Gastroenterol; 2021 May; 27(19):2415-2433. PubMed ID: 34040331
[TBL] [Abstract][Full Text] [Related]
38. Resistance of Lenvatinib in Hepatocellular Carcinoma.
Guo J; Zhao J; Xu Q; Huang D
Curr Cancer Drug Targets; 2022; 22(11):865-878. PubMed ID: 36267045
[TBL] [Abstract][Full Text] [Related]
39. Lenvatinib for Hepatocellular Carcinoma Patients with Nonviral Infection Who Were Unlikely to Respond to Immunotherapy: A Retrospective, Comparative Study.
Hatanaka T; Kakizaki S; Nagashima T; Namikawa M; Ueno T; Tojima H; Takizawa D; Naganuma A; Arai H; Harimoto N; Shirabe K; Uraoka T
Oncology; 2021; 99(10):641-651. PubMed ID: 34515171
[TBL] [Abstract][Full Text] [Related]
40. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
